Ronald Bailey | October 4, 2006
Talk about "medical marijuana." -- Researchers at the the Scripps Research Institute report that the chief active ingredient in marijuana, "THC and its analogues may provide an improved therapeutic for Alzheimer's disease." In tests, THC handily beat the current FDA-approved Alzheimer's medications tacrine and donepezil in slowing the aggregation of amyloid plaques associated with that form of progressive dementia.
All right, I don't know for sure that Drug Czar John Walters is demented, but his continuing ineffectual war on weed is a pretty good sign that he's got psychological problems.
Help Reason celebrate its next 40 years. Donate Now!
Try Reason's award-winning print edition today! Your first issue is FREE if you are not completely satisfied.
Cecil B Demented was horribly underrated. I laughed my ass off. Lay off the guy. He's the only product of Baltimore that I know of other than Mencken.
Now, now -- that was John *WATERS*, a totally different, and
entirely more estimable person.
John Walters has never in his life reached the heights of moral
behavior of any of Waters' characters, nor has he contributed even
as little as the Marbles.
BTW, of course Walters is demented -- he's a demented f**kwit, as
witnessed by his being a republican employed by the
government.
It's a pre-requisite.
hugs,
Shirley Knott
Maybe the marijuana revolution will be launched by the elderly lobby-after the Reefer Madness generation completely dies off.
...his continuing ineffectual war on weed is a pretty good
sign that he's got psychological problems.
Damn skippy. The son of a bitch should do hard time in a federal
pound-em-in-the-ass prison.
I also saw "Waters", we seem to have stumbled upon some bug in the gestalt of perception.
So, if it turns out that mj has preventive or curative properties relative to Alzheimers, could aggrieved patients in states where medical mj is legal (e.g., California), sue the government for the harm caused by the deprivation of necessary medicine? I'd buy tickets to that trial.
Site comments/questions:
Media Inquiries and Reprint Permissions:
(310) 367-6109
Editorial & Production Offices:
3415 S. Sepulveda Blvd.
Suite 400
Los Angeles, CA 90034
(310) 391-2245